Cullen/Frost Bankers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.12K Buy
+26
New +$3.52K ﹤0.01% 1233
2021
Q1
Sell
-10
Closed -$1K 1149
2020
Q4
$1K Hold
10
﹤0.01% 1050
2020
Q3
$1K Buy
+10
New +$1.12K ﹤0.01% 1133
2020
Q1
Sell
-291
Closed -$28K 1043
2019
Q4
$28K Buy
291
+239
+460% +$20.7K ﹤0.01% 728
2019
Q3
$4K Buy
+52
New +$4.32K ﹤0.01% 937

Other funds holding XBI

Cullen/Frost Bankers's XBI Position: Q2 2026 in Review

Cullen/Frost Bankers opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 26 shares worth $4.12K. The stake represents ﹤0.01% of the portfolio and ranks #1233 among its holdings. This is a return to the name: Cullen/Frost Bankers previously reported a position in XBI as recently as Q4 2020.

Cullen/Frost Bankers first reported a position in XBI in Q3 2019 and has held it in 5 quarters since. The position peaked at $28K in Q4 2019. 341 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Cullen/Frost Bankers held 26 shares of State Street SPDR S&P Biotech ETF worth $4.12K as of Q2 2026.
  • State Street SPDR S&P Biotech ETF was a new Cullen/Frost Bankers position in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1233 holding.
  • Cullen/Frost Bankers first reported a position in State Street SPDR S&P Biotech ETF in Q3 2019 and has held it in 5 quarters since.
  • Cullen/Frost Bankers's State Street SPDR S&P Biotech ETF position peaked at $28K in Q4 2019.
  • 341 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.